Navigation Links
Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/10/2010

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2010 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, 2010, 10:30 a.m. ET, at the St. Regis hotel in New York City.

Mr. Moch will give an update on the company's pipeline and technology assets, including CMX001, a broad-spectrum antiviral being developed for the treatment of a wide range of infections caused by double-stranded DNA (dsDNA) viruses.  CMX001 is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of dsDNA viruses, including cytomegalovirus and adenovirus.

About Chimerix and CMX001

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  

The company's lead candidate, CMX001, is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of life-threatening viruses, including cytomegalovirus and adenovirus.  Over 300 people have received CMX001 to date.  CMX001 has been well tolerated in all studies, with a growing body of evidence of the compound's antiviral activity in humans.  CMX001 has been administered to more than 200 people, including healthy volunteers and patients, in Chimerix's ongoing placebo-controlled studies.  In addition, at the request of leading physicians at over 45 medical centers throughout the United States, Canada, Europe and Israel, CMX001 has been administered to more than 100 patients under investigator-held Emergency Investigational New Drug applications (EINDs) for the treatment of a wide range of infections caused by dsDNA viruses for which t
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 Kepner-Tregoe (KT), ... announced that 13-year veteran Chris Geraghty ... Geraghty,s experience includes more than 20 years serving ... with manufacturing organizations. He succeeds Ray ... as Kepner-Tregoe,s Chairman of the Board and CEO. ...
(Date:5/21/2013)... , May 21, 2013  IsoRay, Inc. (AMEX: ... that it has entered into an exclusive international distribution ... complete product line in Greece . ... seed brachytherapy and medical radioisotope applications for brain cancer, ... gynecologic ("gyn") cancer. IASIS Medical is ...
(Date:5/21/2013)... Inc. (OTC BB: VASO) (the "Company"), a diversified medical technology ... devices and in the domestic sale of diagnostic imaging products, ... President and CEO of Vasomedical, Inc. will present at the ... 2013 in New York City at ... is scheduled to begin at 9:30 a.m. EDT. ...
Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2
... Nephros, Inc. (OTC Bulletin Board: NEPH ... products for therapeutic applications, infection control, and water purification, ... reverse split of its common stock will take effect ... 2011. Nephros common stock will be quoted on the ...
... The Florida Society of Pain Management Providers ( www.Flspmp.org ... use in the United States. Until now these statistics ...  Oxycodone dispensed in U.S. 2009 by state (per 100,000 ... FDA.Translation from grams to 15mg tablets for comparison purposes ...
Cached Medicine Technology:Nephros Announces Completion of Reverse Stock Split 2Nephros Announces Completion of Reverse Stock Split 3Nephros Announces Completion of Reverse Stock Split 4Florida Pain Clinic Society: 3.7 Billion Oxycodone Tablets Dispensed in U.S. 2
(Date:5/21/2013)... 2013 According to a May 13, 2013 ... of Botox,” Botox injections have become the most ... 2002 (Go to goo.gl/8iYbD). Although it is mostly associated with ... The injection makes facial wrinkles less visible by paralyzing facial ... about three months. This means that people who are conscious ...
(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...
(Date:5/21/2013)... 2013 MedMar Healing Center announces ... Second Harvest Food Bank. Twenty-eight businesses, including MedMar Healing Center, ... food drive. The goal is to raise food to help ... facing their families in recent years. , “We like ... those in need,” explains Douglas Chloupek of MedMar Healing Center. ...
(Date:5/21/2013)... thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, ... acid fragment of prosaposin that significantly reduces metastatic ... lung cancer. The findings suggest that a prosaposin-based ... of cancers. , The study team, led ... Vivek Mittal, PhD, at Weill Cornell Medical College ...
(Date:5/21/2013)... The Brazilian funding agency for scientific and technological research ... of So Paulo, announced an investment estimated in US$ ... Centers (RIDCs) for a period of up to eleven ... and 7. , Funding for the 17 RIDCs ... funding faculty, technicians, support personnel, and infrastructure). Host institutions ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Research at the cutting edge of knowledge 2
... fix for depression. Even if you are under medical care ... ,The December issue of Mayo Clinic Women's HealthSource offers five ... the risk of recurrence. ,1. Keep active. ... most days has been shown to improve mood. Long-term regular ...
... form of food poison. Then, fame came as a ... the 'miracle poison' and used for an increasing number ... of Mayo Clinic Health Letter covers how this drug ... ,Botulinum toxin blocks communication between nerves and muscles. ...
... drugs causing jaw problems have you wondering: Should you stop ... been reports of partial death of a jawbone (osteonecrosis) related ... to the December issue of Mayo Clinic Health Letter. ... — a disease that causes bones to become brittle and ...
... University of Rochester, Low doses of the drug mifepristone ... //and greatly improves the quality of life in women. ... of the journal, Obstetrics and Gynecology. ,Leiomyoma, ... of all women aged 35 to 49. The non-cancerous ...
... by the Department of Radiology at the University of ... the accuracy of diagnosing meniscal tears. ... there is one MR image with an abnormal finding. ... of 174 patients who had knee MR exams then ...
... one more reason why teenage years are perceived as ... the Pandora's Box has opened. //Such teens are prone ... no'vice' contemporaries, a recent insight indicates. ,The Canadian ... abuse tendencies among 15- to 19-year-olds, drawing on the ...
Cached Medicine News:Health News:Five Self-Care Strategies For Depression 2Health News:Mifepristone Reliable For Treating Uterine Fibroids 2Health News:Mifepristone Reliable For Treating Uterine Fibroids 3
DePuy 2 Bone Cement is a unique fast-set digital cement that is the excellent choice for small joint procedures such as the patella, glenoid or other extremity joints....
... Palacos® Bone Cement has clinically proven ... cemented arthroplasty. Palacos® is now available ... an antibiotic loaded bone cement cleared ... of a two-stage revision after infection ...
... System for Two-Dimensional Mapping of the ... uniquely merges two sophisticated measurement techniques, ... flowmetry, to a new kind of ... of the retinal micro-circulation., ,Using an ...
... block tear drainage through the canaliculus, synthetic absorbable ... symptoms:, Indicated for use in the treatment ... components of various ocular surface diseases, May be ... related complications and to enhance the retention of ...
Medicine Products: